# Study Comparing Racivir and Lamivudine in Treatment-Experienced HIV Subjects

> **NCT00121979** · PHASE2 · COMPLETED · sponsor: **Pharmasset** · enrollment: 60 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Racivir, a non-nucleoside reverse transcriptase inhibitor

## Key facts

- **NCT ID:** NCT00121979
- **Lead sponsor:** Pharmasset
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** —
- **Final completion:** 2006-03
- **Target enrollment:** 60 (—)
- **Last updated:** 2007-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00121979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00121979, "Study Comparing Racivir and Lamivudine in Treatment-Experienced HIV Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00121979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*